Core Viewpoint - The FDA's swift action against mass compounding practices is seen as a positive development for the industry, emphasizing the importance of patient safety and intellectual property rights [1][3][5]. Company Actions - The company has filed a lawsuit against Hims and Hers for patent infringement related to Semaglutide, despite Hims and Hers scrapping their pill version, indicating a commitment to protecting its intellectual property [4]. - The company emphasizes that compounding should be limited to specific cases rather than mass marketing, highlighting concerns over patient safety and the quality of active pharmaceutical ingredients (APIs) [5][6]. Market Dynamics - The company reported a successful launch of its oral GLP-1 pill, with 246,000 users within five weeks, significantly outperforming previous injectable launches [9][11]. - The initial price of the pill is set at $149, which is considered affordable, and the uptake has been 15 times better than the Wegovy injection launch [11][12]. - The company anticipates a year of pricing headwinds but expects volume growth to provide a tailwind in the future [10]. Manufacturing and Supply Chain - The pill is uniquely manufactured in the U.S. from start to finish, which is uncommon in the industry where many competitors source APIs from abroad [16][17]. Strategic Outlook - The company is actively seeking acquisition opportunities to enhance its R&D capabilities and is open to external innovations that complement its internal developments [18][19]. - Valuations of potential acquisition targets are well understood by the company, which maintains financial discipline in its bidding strategies [21][22]. - The timeline for potential deals is flexible, focusing on finding the right target rather than a specific quantity of deals [23].

Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at riskNovo Nordisk takes decisive legal action to stop Hims’ illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetesNovo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that inf ...

Core Viewpoint - Ovation Science Inc. has received a new Canadian patent that enhances its market exclusivity and expands its global intellectual property portfolio, supporting long-term revenue growth [1] Group 1: Patent Issuance - The newly issued Canadian patent covers proprietary topical formulations containing CBD and THC [1] - The patent is titled "Composition and method for transdermal delivery of cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC)" [1] - This patent expands Ovation's intellectual property protection beyond its previously issued U.S. patent [1] Group 2: Market Implications - The issuance of the patent significantly strengthens the Company's growing international patent portfolio [1] - The patent enhances the Company's market exclusivity and licensing potential [1]

As filed with the U.S. Securities and Exchange Commission on December 1, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 UPEXI, INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 5900 83-3378978 (I.R.S. Employer Identification Number) 3030 North Rocky Point ...

SAVE FOODS, INC. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. 333-276474 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Nevada 2000 26-4684680 HaPard ...

S-1/A 1 tenx_s1a.htm FORM S-1/A As filed with the U.S. Securities and Exchange Commission on February 1, 2024 Registration No. 333-275856 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tenax Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 26-2593535 (Primary Standard Industrial Classification Code Nu ...